Global Liraglutide Drugs Market Size By Type (Victoza, Saxenda), By Application (Type 2 Diabetes, Obesity), By Region, And Segment Forecasts, 2023 to 2032

The Global Liraglutide Drugs Market was valued at USD 4.1 billion in 2023 and is projected to reach USD 7.3 billion by 2031, growing at a CAGR of 7.2% during the forecast period (2023–2031). The market is primarily driven by the rising prevalence of type 2 diabetes and obesity worldwide, along with increasing adoption of GLP-1 receptor agonists as frontline therapy. Liraglutide, a long-acting glucagon-like peptide-1 analog, continues to gain traction owing to its dual effectiveness in managing blood glucose levels and promoting weight loss. As public and private sectors boost awareness campaigns and preventive healthcare measures, the market outlook remains robust.

Drivers:

1. Rising Global Burden of Diabetes and Obesity:

The escalating incidence of lifestyle-induced health conditions such as type 2 diabetes and obesity significantly contributes to the demand for liraglutide drugs. Countries with aging populations and sedentary lifestyles are witnessing a surge in diagnoses, making liraglutide a preferred therapeutic option.

2. Increasing Preference for Once-Daily Injectable Therapies:

Patients and healthcare providers are increasingly leaning toward once-daily GLP-1 therapies like liraglutide for their convenience and compliance benefits over multiple daily dose regimens.

3. Expanding Clinical Applications:

Beyond diabetes, liraglutide has shown promising results in treating conditions such as chronic weight management and cardiovascular risks, leading to extended market adoption.

Restraints:

1. High Treatment Costs:

Despite its efficacy, the high cost of liraglutide remains a significant barrier, particularly in developing markets where healthcare reimbursement is limited.

2. Injection-Based Administration:

The reluctance of patients toward injectable therapies and needle phobia can hinder market growth, especially when oral alternatives are gaining traction.

Opportunity:

1. Growing Demand in Emerging Markets:

Increasing healthcare awareness, rising disposable income, and expanding insurance coverage in regions such as Asia-Pacific and Latin America present untapped growth opportunities.

2. Product Innovation and Combination Therapies:

Pharmaceutical companies are focusing on expanding the indications of liraglutide and developing combination therapies that further improve patient outcomes.

Market by System Type Insights:

Based on product type, the Victoza (liraglutide 1.2/1.8 mg) segment led the market in 2023 due to its widespread prescription for glycemic control in type 2 diabetes. However, the Saxenda (liraglutide 3.0 mg) segment is poised for the fastest growth rate during the forecast period, driven by a sharp increase in its use for chronic weight management under medically supervised plans.

Market by End-Use Insights:

In terms of end use, the Hospitals segment dominated the market in 2023, attributed to increased hospital-based diagnoses, treatment plans, and patient follow-up protocols. Meanwhile, Retail Pharmacies are emerging as a strong distribution channel, benefiting from rising consumer preference for at-home therapy management and enhanced pharmacy-based consultation services.

Market by Regional Insights:

North America held the largest market share in 2023 due to its advanced healthcare system, strong pharmaceutical infrastructure, and high obesity prevalence. However, Asia-Pacific is expected to witness the highest CAGR during the forecast period, fueled by rapid urbanization, increasing diabetes awareness, and government initiatives aimed at preventive healthcare.

Competitive Scenario:

Major players in the Global Liraglutide Drugs Market include:

Novo Nordisk A/S

Pfizer Inc.

Eli Lilly and Company

Sanofi

AstraZeneca PLC

These companies focus on strategic collaborations, market expansion in emerging economies, and clinical research to enhance therapeutic efficacy and reduce side effects. Notably:

In 2023, Novo Nordisk expanded its manufacturing capacity in North America to meet rising demand for Saxenda and Victoza.

In 2024, Pfizer initiated Phase II trials for a novel oral GLP-1 analog inspired by liraglutide’s mechanism of action.

In 2025, Eli Lilly announced a co-development partnership for a dual-injection formulation combining liraglutide with an SGLT2 inhibitor.

Scope of Work – Global Liraglutide Drugs Market

Key Market Developments:

2023: Novo Nordisk expanded Saxenda distribution in Southeast Asia through a strategic partnership with leading local healthcare providers.

2024: AstraZeneca announced clinical studies to explore combination therapies featuring liraglutide analogs for dual metabolic control.

2025: Sanofi launched a patient-support mobile platform integrated with liraglutide therapy management tools for increased adherence.

FAQs:

1. What is the current market size of the Global Liraglutide Drugs Market?

The market size was valued at USD 4.1 billion in 2023.

2. What is the major growth driver of the Global Liraglutide Drugs Market?

The rising prevalence of type 2 diabetes and obesity, along with increasing adoption of once-daily GLP-1 receptor agonists.

3. Which is the largest region during the forecast period in the Global Liraglutide Drugs Market?

North America is currently the largest region, though Asia-Pacific is expected to grow at the fastest rate.

4. Which segment accounted for the largest market share in Global Liraglutide Drugs Market?

The Victoza segment held the largest share in 2023.

5. Who are the key market players in the Global Liraglutide Drugs Market?

Key players include Novo Nordisk A/S, Pfizer Inc., Eli Lilly and Company, Sanofi, and AstraZeneca PLC.